84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]章勝權,王煦程,葉福生,等.從脂代謝角度探討補腎活血方治療絕經(jīng)后骨質疏松癥的作用機制[J].中醫(yī)正骨,2022,34(07):1-5.
　ZHANG Shengquan,WANG Xucheng,YE Fusheng,et al.Investigation on the mechanism of Bushen Huoxue Fang(補腎活血方)for treatment of postmenopausal osteoporosis from the view of lipid metabolism[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(07):1-5.
點擊復制

從脂代謝角度探討補腎活血方治療絕經(jīng)后骨質疏松癥的作用機制()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第34卷
期數(shù):
2022年07期
頁碼:
1-5
欄目:
基礎研究
出版日期:
2022-07-20

文章信息/Info

Title:
Investigation on the mechanism of Bushen Huoxue Fang(補腎活血方)for treatment of postmenopausal osteoporosis from the view of lipid metabolism
作者:
章勝權1; 王煦程2; 葉福生3; 袁文華4
(1.杭州市富陽中醫(yī)骨傷醫(yī)院,浙江 杭州 311400; 2.浙江中醫(yī)藥大學,浙江 杭州 310053; 3.浙江蕭山醫(yī)院,浙江 杭州 311200; 4.浙江省中醫(yī)院,浙江 杭州 310006)
Author(s):
ZHANG Shengquan1; WANG Xucheng2; YE Fusheng3; YUAN Wenhua4
1.Fuyang TCM Orthopedic-Traumatological Hospital,Hangzhou 311400,Zhejiang,China 2.Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang,China 3.Zhejiang Xiaoshan Hospital,Hangzhou 311200,Zhejiang,China 4.Zhejiang Provincial Hospital of Chinese Medicine,Hangzhou 310006,Zhejiang,China
關鍵詞:
骨質疏松; 絕經(jīng)后;  補腎活血方;  脂類代謝;  小鼠;  動物實驗
Keywords:
osteoporosis; postmenopausal;  Bushen Huoxue Fang;  lipid metabolism;  mice;  animal experimentation
摘要:
目的:從脂代謝角度探討補腎活血方治療絕經(jīng)后骨質疏松癥(postmenopausal osteoporosis,PMOP)的作用機制。方法:將15只9周齡SPF級健康雌性C57BL/6J小鼠隨機分為3組,每組5只。模型組和補腎活血方組小鼠結扎兩側輸卵管后,剪去卵巢進行PMOP造模; 假手術組小鼠結扎兩側輸卵管后剪除卵巢旁部分脂肪組織。從造模術后第2天開始,補腎活血方組使用折合生藥濃度為1.5 g·mL-1的補腎活血方濃縮劑灌胃,每次0.4 mL,每天1次; 假手術組和模型組小鼠以等量生理鹽水灌胃。3組小鼠均每天灌胃1次,連續(xù)灌胃8周。藥物干預結束后第2天,將所有小鼠脫頸處死,取股骨遠端進行觀察。以Micro-CT進行骨組織微結構觀察,通過阿爾新藍-蘇木素染色觀察髓腔中脂肪空泡數(shù)量,通過免疫組織化學染色觀察骨組織中脂肪酸結合蛋白4(fatty acid-binding protein 4,FABP4)表達情況。結果:①一般情況。實驗期間小鼠飲食、精神狀況正常,活動規(guī)律,至處死前無小鼠死亡。②骨組織微結構觀察結果。Micro-CT圖像顯示,與假手術組相比,模型組小鼠股骨骨密度明顯降低,骨小梁減少; 補腎活血方組小鼠的股骨骨密度和骨小梁數(shù)量與假手術組相當。假手術組、模型組、補腎活血方組小鼠的股骨骨密度比較,差異有統(tǒng)計學意義[(0.033±0.009)g·cm-3,(0.003±0.001)g·cm-3,(0.022±0.009)g·cm-3,F=14.240,P=0.005]; 模型組的股骨骨密度低于假手術組和補腎活血方組(P=0.046,P=0.050); 補腎活血方組和假手術組的股骨骨密度比較,差異無統(tǒng)計學意義(P=0.203)。③髓腔中脂肪空泡數(shù)量觀察結果。阿爾新藍-蘇木素染色結果顯示,模型組髓腔內(nèi)脂肪空泡數(shù)量較假手術組增加; 補腎活血方組髓腔內(nèi)脂肪空泡數(shù)量少于模型組,與假手術組接近。④骨組織中FABP4表達情況檢測結果。假手術組、模型組、補腎活血方組股骨組織中的FABP4含量比較,差異有統(tǒng)計學意義[(1.287±0.015)%,(11.897±0.703)%,(0.990±0.162)%,F=800.200,P=0.000]。模型組的FABP4含量高于假手術組和補腎活血方組(P=0.001; P=0.001),假手術組的FABP4含量高于補腎活血方組(P=0.034)。結論:通過調控FABP4表達,抑制骨髓間充質干細胞向脂肪細胞分化,可能是補腎活血方治療PMOP的作用機制之一。
Abstract:
Objective:To explore the mechanism of Bushen Huoxue Fang(補腎活血方,BSHXF)in treatment of postmenopausal osteoporosis(PMOP)from the view of lipid metabolism.Methods:Fifteen 9-week-old healthy SPF-grade female C57BL/6J mice were randomly divided into model group,BSHXF group and sham-operated group,5 cases in each group.The mice in model group and BSHXF group were subjected to bilateral tubal ligation,followed by removing ovaries for inducing PMOP; while the ones in sham-operated group underwent bilateral tubal ligation,followed by removal of peri-ovarian adipose tissues.From the 2nd day after the modeling operation,the mice in BSHXF group were intragastric administrated with BSHXF concentrate(equivalent to the crude drug with concentration of 1.5 g/mL),once a day,0.4 ml at a time; while the ones in sham-operated group and model group with the same dose of normal saline.All mice in the 3 groups were intragastric administrated once a day for consecutive 8 weeks.On day 2 after the end of drug intervention,all mice were executed by cervical dislocation and their distal femurs were harvested for observation.The bone tissue microstructure was observed by micro-CT scanning,and the number of fatty vacuoles in medullary cavity was observed via alcian blue-hematoxylin(ABH)staining,moreover,the expression of fatty acid-binding protein 4(FABP4)in bone tissues was detected by using immunohistochemical staining.Results:①During the experiment,all mice were in normal mental states with euphagia and regular activities,and no death occurred before the execution.②As demonstrated by the Micro-CT images,the femur bone mineral density(BMD)was obviously declined and the bone trabecula decreased in model group compared with those in sham-operated group; while the femur BMD and bone trabecula number in BSHXF group were similar to those of sham-operated group.There was statistical difference in femur BMD between the 3 groups(0.033±0.009,0.003±0.001,0.022±0.009 g/cm(3),F=14.240,P=0.005).The femur BMD was lower in model group compared to sham-operated group and BSHXF group(P=0.046,P=0.050),and there was no statistical difference in femur BMD between BSHXF group and sham-operated group(P=0.203).③The results of ABH staining showed that the number of fatty vacuoles in medullary cavity increased in model group compared to sham-operated group,while it was less in BSHXF group compared to model group,and was similar to that of sham-operated group.④There was statistical difference in the level of FABP4 in femur tissues between the 3 groups(1.287±0.015,11.897±0.703,0.990±0.162%,F=800.200,P=0.000).The level of FABP4 was higher in model group compared to sham-operated group and BSHXF group(P=0.001; P=0.001),and was lowest in BSHXF group(P=0.034).Conclusion:BSHXF can inhibit the differentiation of bone marrow mesenchymal stem cells into adipocytes through regulating the expression of FABP4,which may be one of its mechanisms for treatment of PMOP.

參考文獻/References:

[1] 王柄棋,孫雨晴,陳翔,等.絕經(jīng)后骨質疏松癥藥物治療的現(xiàn)狀與思考[J].中國骨質疏松雜志,2017,23(6):818-823.
[2] 中華中醫(yī)藥學會.絕經(jīng)后骨質疏松癥(骨痿)中醫(yī)藥診療指南(2019年版)[J].中醫(yī)正骨,2020,32(2):1-13.
[3] 許兵,方劍利,劉慧,等.補腎活血方對去勢大鼠骨質疏松的影響[J].中華骨質疏松和骨礦鹽疾病雜志,2011,4(3):177-182.
[4] 王龍梅,劉康佳,劉子欣,等.脂代謝及相關疾病與骨質疏松癥關系研究進展[J].中國骨質疏松雜志,2021,27(5):767-770.
[5] HU X,MA S,YANG C,et al.Relationship between senile osteoporosis and cardiovascular and cerebrovascular diseases[J].Exp Ther Med,2019,17(6):4417-4420.
[6] HU L,YIN C,ZHAO F,et al.Mesenchymal stem cells:cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment[J].Int J Mol Sci,2018,19(2):360.
[7] PAGNOTTI G M,STYNER M,UZER G,et al.Combating osteoporosis and obesity with exercise:leveraging cell mecha-nosensitivity[J].Nat Rev Endocrinol,2019,15(6):339-355.
[8] MURUGANANDAN S,GOVINDARAJAN R,SINAL C J.Bone marrow adipose tissue and skeletal health[J].Curr Osteoporos Rep,2018,16(4):434-442.
[9] FAZELI P K,HOROWITZ M C,MACDOUGALD O A,et al.Marrow fat and bone—new perspectives[J].J Clin Endocrinol Metab,2013,98(3):935-945.
[10] MURUGANANDAN S,SINAL C J.The impact of bone marrow adipocytes on osteoblast and osteoclast differentiation[J].IUBMB Life,2014,66(3):147-155.
[11] MURUGANANDAN S,DRANSE H J,ROURKE J L,et al.Chemerin neutralization blocks hematopoietic stem cell os-teoclastogenesis[J].Stem Cells,2013,31(10):2172-2182.
[12] SHU L,HOO R L,WU X,et al.A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes[J].Nat Commun,2017,8:14147.
[13] JUREK S,SANDHU M A,TRAPPE S,et al.Optimizing adipogenic transdifferentiation of bovine mesenchymal stem cells:a prominent role of ascorbic acid in FABP4 induction[J].Adipocyte,2020,9(1):35-50.
[14] FURUHASHI M,TUNCMAN G,GÖRGÜN C Z,et al.Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2[J].Nature,2007,447(7147):959-965.
[15] ZHAO W,RASHEED A,TIKKANEN E,et al.Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease[J].Nat Genet,2017,49(10):1450-1457.
[16] HAO J,ZHANG Y,YAN X,et al.Circulating Adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development[J].Cell Metab,2018,28(5):689-705.
[17] LIU Z Z,HONG C G,HU W B,et al.Autophagy receptor OPTN(optineurin)regulates mesenchymal stem cell fate and bone-fat balance during aging by clearing FABP3[J].Autophagy,2021,17(10):2766-2782.
[18] SONG C,TAN P,ZHANG Z,et al.Rev-erb agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation[J].FASEB J,2018,32(6):3215-3228.
[19] 許兵,金紅婷,王蕭楓,等.補腎活血含藥血清對成骨細胞經(jīng)典Wnt/β-catenin通路的影響研究[J].中國骨傷,2015,28(6):553-558.
[20] XIA C,ZOU Z,FANG L,et al.Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis[J].Biomed Pharmacother,2020,127:110170.
[21] XU R,ZENG Q,XIA C,et al.Fractions of Shen-Sui-Tong-Zhi formula enhance osteogenesis via activation of β-catenin signaling in growth plate chondrocytes[J].Front Pharmacol,2021,12:711004.

相似文獻/References:

[1]李林軍.應用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(07):12.
[3]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術中的應用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(07):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(07):19.
[6]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質疏松與血微量元素的關系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(07):20.
[7]史曉林,李春雯,張志強.弱陽離子磁珠分離技術和基質輔助激光解吸電離飛行時間質譜技術在原發(fā)性Ⅰ型骨質疏松癥血清標志蛋白篩選中的應用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(07):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質疏松癥的療效及作用機制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(07):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質疏松癥的 相關性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(07):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質疏松癥辨證分型與抑郁焦慮的關系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(07):3.
[11]韓艷,溫利平,劉娜,等.補腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(07):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質疏松癥的免疫學研究進展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(07):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質疏松癥腎虛證的關系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質疏松大鼠骨代謝紊亂的作用機制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(07):1.
[16]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質疏松癥的流行病學概況及發(fā)病機制研究進展[J].中醫(yī)正骨,2018,30(03):52.
[17]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質疏松癥發(fā)生發(fā)展過程中細胞自噬的機制[J].中醫(yī)正骨,2018,30(04):59.
[18]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(07):20.
[19]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(07):11.
[20]趙凡,劉全,吳連國.口服強骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(07):26.

備注/Memo

備注/Memo:
基金項目:浙江省中醫(yī)藥科技計劃項目(2020ZB208); 杭州市醫(yī)藥衛(wèi)生科技項目(B20200552); 浙江中醫(yī)藥大學基本科研能力提升項目(2021JKJNTZ017A) 通訊作者:袁文華 E-mail:[email protected]
更新日期/Last Update: 1900-01-01